31 results about "Gulose" patented technology

Disclosed is a preparation method of a bicyclol glycoside compound, which is characterized in that first bicyclol and glycine protected by Fmoc are condensed under the catalysis of 1-(3-dimethylamino propyl)-3-ethyl carbodiimide hydrochloride and 4-dimethylamino pyridine, and then protecting group of Fmoc is removed under the effect of acetonitrile diethylamine to obtain intermediate bicyclol-glycine ester which is the condensation of the bicyclol and the glycine. At last, Alpha or Beta glycosyl carboxyl methyl glycoside of glucose, galactose, mannose, allose, altrose, gulose, idose, talose, acetyl-glucosamine or acetyl galactosamine has condensation reaction with the intermediate bicyclol-glycine ester in solvent N-methyl pyrrolidone and under the effect of condensing agent and alkali. The water solubility of the bicyclol can be increased with the invention, and the bioavailability of the bicyclol is improved, which can provide enough raw material and effective compound route for the study of the anti-hepatitis drug. The invention has the advantages that the preparation method is simple and convenient; the condition is easy to control.

The invention discloses a glucose group-terminated PLLA diblock copolymer material and a preparation method thereof, belonging to the technical field of high polymer materials. The preparation methodcomprises the following steps: firstly, subjecting PLLA and 1,2:5,6-di-O-isopropylidene-D-gulose (IPG) serving as raw materials to a reaction under the conditions that a molar ratio of IPG to PLLA isgreater than 4: 1, a polymerization pressure is 10-300 Pa, and a polymerization temperature is 160-200 DEG C; and carrying out a melt polymerization reaction for 4-12 hours to prepare a poly(L-lacticacid)-isopropylidene glucose diblock copolymer (PLLAIPG), and removing a hydroxyl protection group of the PLLAIPG to obtain the glucose group-terminated PLLA diblock copolymer (PLLAG). The PLLAG material has a melting temperature of about 150 DEG C and a crystallinity of about 50%, which are similar to those of PLLA, but the hydrophilicity of the PLLAG material is superior to the hydrophilicity ofPLLA; and the contact angle of the PLLAG material is about 65 degrees while the contact angle of PLLAG is 88 degrees.

The invention discloses gulose tablet excipient, which consists of the following ingredients in percentage by weight: 88 percent to 96 percent of gulose, 1 percent to 5 percent of starch octenyl succinate anhydride, 1 percent to 5 percent of silicon dioxide and 1 percent to 5 percent of porcellanite, and has the advantages that the mobility is good, the forming degree is good, the demolding performance is good, and the gulose tablet excipient can be directly tableted with medicine and water for preparing medicine tablets. The invention also discloses a medicine tablet, which is prepared from the following ingredients in percentage by weight: 75 percent to 85 percent of medicine active ingredients, 5 percent to 15 percent of gulose tablet excipient and 5 percent to 15 percent of water raw materials, wherein the gulose tablet excipient and the medicine active ingredients do not have incompatibility and reaction, in addition, the solvability is good, the flowability is good, and the medicine tablet is suitable for the direct tableting of various kinds of medicine. The invention also discloses a preparation method of the medicine tablet, which has the advantages that the preparation is simple, the implementation is easy, and the operation and the control are easy.

Object: To provide a thermostable L-ribose isomerase.Means for Resolution: The thermostable L-ribose isomerase with MW. 32,000 (by SDS-PAGE), optimal temperature of 45° C., optimal pH of pH 9.0 (glycine-NaOH buffer), and stable physicochemical properties such as temperature stability up to 45° C. during thermal treatment at pH 9.0 for 10 minutes, and with an action to isomerize L-ribose to generate L-ribulose or of inversely to isomerize L-ribulose to generate L-ribose. A conversion method between an aldose and a ketose comprising allowing the thermostable L-ribose isomerase as an enzyme derived from (1) Raoultella ornithinolytica strain MB426 (NITE BP-277) to interact with an aldose selected from L-ribose, D-lyxose, D-tallose, D-mannose, L-allose and L-gulose to isomerize the aldose to generate a ketose selected from the individually corresponding L-ribulose, D-xylulose, D-tagatose, D-fructose, L-psicose and L-sorbose or to interact with a ketose selected from L-ribulose, D-xylulose, D-tagatose, D-fructose, L-psicose and L-sorbose to isomerize the ketose to generate an aldose selected from the individually corresponding L-ribose, D-lyxose, D-tallose, D-mannose, L-allose and L-gulose.

The invention relates to an immobilized enzyme composition for preparing hexose. The hexoses include, for example, tagatose, psicose, fructose, allose, mannose, galactose, antrose, talose, sorbose, gulose, idulose, and inositol. The invention also relates to an enzymatic process for the preparation of hexose from a saccharide by contacting a starch derivative with an immobilized enzyme composition of the invention.

In a radioactive diagnostic imaging agent comprising a radioactive halogen-labeled compound as an active ingredient, to prevent the radiation degradation of the active ingredient to increase the stability of the radioactive diagnostic imaging agent. A biologically acceptable saccharide or sugar alcohol is added to the radioactive diagnostic imaging agent in an amount effective for the prevention of the radiation degradation. The amount of the saccharide or sugar alcohol to be added is preferably 10 (mmol / L) / GBq / mL or more, more preferably 50 (mmol / L) / GBq / mL or more. The saccharide is preferably selected from the group consisting of erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose and tagatose. The sugar alcohol is preferably selected from the group consisting of erythritol, xylitol, sorbitol and mannitol.

The invention relates to the medicine technology field, in particular relates to a new application of cardiac glycoside chemical compound having general formula (I) in preparing oncotherapy drug, wherein, R equals to 2-O-methyl-Beta-D-mycose, 6-deoxidation-Beta-D-gulose or 6-deoxidation-2-O-methyl-Beta-D-allose. The cardiac glycoside chemical compound can be obtained through a separation from upasin various conventional separation methods or be obtained through a synthesis or semisynthesis method.

The present invention relates to improving the enzymatic activity of Escherichia coli O157:H7-derived sugar isomerase by molecular mechanics and site-directed mutagenesis. More particularly, the present invention relates to a sugar isomerase having an enzymatic activity improved by mutation, a nucleic acid molecule encoding the same, a vector comprising the nucleic acid molecule, a transformant comprising the vector, a mutant of the sugar isomerase, and a method for producing L-gulose using the improved sugar isomerase.

The invention discloses gulose tablet excipient, which consists of the following ingredients in percentage by weight: 88 percent to 96 percent of gulose, 1 percent to 5 percent of starch octenyl succinate anhydride, 1 percent to 5 percent of silicon dioxide and 1 percent to 5 percent of porcellanite, and has the advantages that the mobility is good, the forming degree is good, the demolding performance is good, and the gulose tablet excipient can be directly tableted with medicine and water for preparing medicine tablets. The invention also discloses a medicine tablet, which is prepared from the following ingredients in percentage by weight: 75 percent to 85 percent of medicine active ingredients, 5 percent to 15 percent of gulose tablet excipient and 5 percent to 15 percent of water raw materials, wherein the gulose tablet excipient and the medicine active ingredients do not have incompatibility and reaction, in addition, the solvability is good, the flowability is good, and the medicine tablet is suitable for the direct tableting of various kinds of medicine. The invention also discloses a preparation method of the medicine tablet, which has the advantages that the preparation is simple, the implementation is easy, and the operation and the control are easy.

The invention discloses oligomeric acid iodine as well as a preparation method and application thereof. The molecular structural formula of the provided oligomeric acid iodine is shown in the formula I, wherein m>=2, n>=2, and R1, R2, R3 and R4 are oligomeric glucose (acid) groups, oligomeric N-acetyl glucose (acid) groups, oligomeric D-amino glucose (acid) groups, oligomeric galactose (acid) groups, oligomeric gulose (acid) groups, oligomeric mannose (acid) groups or oligomeric xylose (acid) groups. The preparation method of the oligomeric acid iodine comprises the following steps of: mixingoligomeric acid or oligomeric acid salt with iodine in a mixed solvent of water and alcohol, stirring, controlling the temperature at 50-70 DEG C, and reacting to obtain the oligomeric acid iodine. The oligomeric acid iodine ensures the stability of iodine in the structural matter and has extremely strong effect of contact skilling plant pathogenic bacteria, keeps and strengthens the plant disease resistance induced by oligose, and has rapid and persistent effect for controlling plant diseases. The formula I is disclosed in the specification.

The invention provides a carbohydrate composition with a wound healing promoting effect and application of the carbohydrate composition. The carbohydrate composition contains at least five types of carbohydrate including carboxymethyl chitosan, rhizoma bletillae polysaccharides, fucoidan from fucus vesiculosus, heparan sulfate, chondroitin sulfate, oligosaccharides of hyaluronan and gulose aldehyde acid oligosaccharides. The carbohydrate composition and the application have the advantages that VEGFA (vascular endothelial growth factor A), FGF2 (fibroblast growth factor 2) and VE-cadherin protein mRNA (messenger ribonucleic acid) expression can be obviously improved by the carbohydrate composition, VEGF (vascular endothelial growth factor) secretion and skin fibroblast (HSF) and human immortalized keratinocyte (HaCaT) proliferation can be obviously promoted by the carbohydrate composition, and the obvious wound healing promoting effect can be realized by the carbohydrate composition; raw materials required by the carbohydrate composition are easily available, composition methods for the carbohydrate composition are simple, the carbohydrate composition is low in cost, easy to industrialize and wide in application range, and the like.

The invention discloses a preparation method of 2-hydroxygulose acceptor derivatives, which comprises protecting benzyl-β-galactoside benzyl fork group, inversion of 3-position configuration, deacetylation and selective acetylation series of reactions. At the same time, the invention also discloses a method for preparing bleomycin disaccharide and its precursor by using the 2-hydroxygulose receptor derivative prepared by the method as the receptor. The preparation method of the 2-hydroxygulose acceptor derivative of the present invention solves the defects of rare natural L-gulose source, high cost, unsuitable for industrialization, etc., and simultaneously solves the problem of bleomycin disaccharide and its precursor yield Low, poor operability and repeatability of the reaction, unsuitable for industrialization and other problems. It has the advantages of cheap and easy-to-obtain raw materials, high yield, strong operability, easy control of conditions, industrial scale-up, high efficiency and low cost.

In a radioactive diagnostic imaging agent comprising a radioactive halogen-labeled compound as an active ingredient, to prevent the radiation degradation of the active ingredient to increase the stability of the radioactive diagnostic imaging agent. A biologically acceptable saccharide or sugar alcohol is added to the radioactive diagnostic imaging agent in an amount effective for the prevention of the radiation degradation. The amount of the saccharide or sugar alcohol to be added is preferably 10 (mmol / L) / GBq / mL or more, more preferably 50 (mmol / L) / GBq / mL or more. The saccharide is preferably selected from the group consisting of erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose and tagatose. The sugar alcohol is preferably selected from the group consisting of erythritol, xylitol, sorbitol and mannitol.

The invention discloses a method for synthesizing 1,3,4,6-tetraacetyl-L-gulose. According to the method, a compound, namely, 1,3,4,6-tetraacetatyl-L-gulose is prepared from glucuronolactone serving as a raw material by performing the steps of acetonide protection, benzyl protection, lactone reduction, hemiacetal hydroxyl protection, acetonide de-protection, lactone reduction, hemiacetal hydroxyl de-protection, acetyl protection and benzyl deprotection. In the method, experience reagents are not used, so that the cost is reduced; involved operation is simple and convenient, conditions are easy to control, and industrial production is easy; the total yield is high, and can be magnified to gram grade and over.

The present invention discloses a process for producing sodium 2-keto-L-gulonate from sorbitol and recovering 2-keto-L-gulonic acid in high recovery yields, by controlled cation exchange treatment of the micro-organism free fermentation broth and / or adjusting PII of said purified fermentation broth, followed by direct crystallisation of 2-keto-L-gulonic acid monohydrate.

Disclosed is a preparation method of a bicyclol glycoside compound, which is characterized in that first bicyclol and glycine protected by Fmoc are condensed under the catalysis of 1-(3-dimethylamino propyl)-3-ethyl carbodiimide hydrochloride and 4-dimethylamino pyridine, and then protecting group of Fmoc is removed under the effect of acetonitrile diethylamine to obtain intermediate bicyclol-glycine ester which is the condensation of the bicyclol and the glycine. At last, Alpha or Beta glycosyl carboxyl methyl glycoside of glucose, galactose, mannose, allose, altrose, gulose, idose, talose, acetyl-glucosamine or acetyl galactosamine has condensation reaction with the intermediate bicyclol-glycine ester in solvent N-methyl pyrrolidone and under the effect of condensing agent and alkali. The water solubility of the bicyclol can be increased with the invention, and the bioavailability of the bicyclol is improved, which can provide enough raw material and effective compound route for the study of the anti-hepatitis drug. The invention has the advantages that the preparation method is simple and convenient; the condition is easy to control.